Tectonic Therapeutic closed at $20.30 on Nov 4, up 6.95%, 46.5% below its 52-week closing high. Volume of 221.8K shares was 1.25× its 20-day average (close to normal).
Split-adjusted performance: -9.4% over one month, -30.0% over six months, +15.9% over one year.
Short interest was 2.2M shares at the Oct 15 settlement (19.1% of float, 10.6 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TECXTectonic Therapeutic | $20.30 | +6.95% | −30.0% | — | — | — | $396.9M | |
| ZURAZura Bio Limited | $4.02 | +0.75% | −17.8% | — | — | — | $387.2M | Compare |
| CCCCC4 Therapeutics | $3.12 | −2.80% | +6.5% | +2.8% | −355.9% | — | $383.8M | Compare |
| ALLOAllogene Therapeutics | $1.19 | +6.25% | −48.5% | — | −919.8% | — | $411.1M | Compare |
| EDITEditas Medicine | $2.72 | +4.62% | −14.3% | +232.3% | −153.3% | — | $417.7M | Compare |
| SRZNSurrozen | $31.65 | +5.08% | −7.3% | +408.6% | 640.8% | — | $372.0M | Compare |
| FENCFennec Pharmaceuticals | $10.35 | −3.27% | +44.2% | +85.2% | 11.0% | — | $362.9M | Compare |
| EIKNEikon Therapeutics | $6.39 | +15.14% | −35.9% | — | — | — | $346.1M | Compare |
| XFORX4 Pharmaceuticals | $3.24 | +2.21% | −26.0% | +346.3% | −183.5% | — | $321.2M | Compare |
No recent articles focused on Tectonic Therapeutic.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
